This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
PFAS are used in Class B firefighting foams due to their hydrophobic and lipophobic properties, as well as the stability of the chemicals when exposed to high heat. Though studies have been frequently limited by underpowered study designs, research indicates firefighters have higher blood levels of PFOS and PFHxS than the general population. PFAS exposure is prevalent among firefighters not only due to its use in emergencies but also because it is used in personal protective equipment. In support of these findings, states like Washington and Colorado have moved to restrict and penalize the use of Class B firefighting foam for firefighter training and testing. The September 11 attacks and resulting fires caused the release of toxic chemicals used in materials such as stain-resistant coatings. First responders to this incident were exposed to PFOA, PFNA, and PFHxS through inhalation of dust and smoke released during and after the collapse of the World Trade Center. First responders who were working at or near ground zero were assessed for respiratory and other health effects from exposure to emissions at the World Trade Center. Early clinical testing showed a high prevalence of respiratory health effects. Early symptoms of exposure often presented with persistent coughing and wheezing. PFOA and PFHxS levels were present in both smoke and dust exposure, but first responders exposed to smoke had higher concentrations of PFOA and PFHxS than those exposed to dust.
Eight people, including two children, were killed while 29 others were injured in Russian missile attacks on Dnipropetrovsk Oblast, particularly in Dnipro and Synelnykove. A total of 22 missiles and 14 Shahed drones were fired, including six Kh-22 missiles and two Iskander-K missiles; according to Ukraine, 29 were intercepted including two Kh-22s, which were intercepted by the Patriot air defense system, the first time these missiles were intercepted since the start of the invasion. Two people were killed in separate attacks in Mykolaiv Oblast and Kherson. A Russian Tupolev Tu-22M3 long range strategic bomber crashed in Stavropol Krai while returning to base, killing one crew member, with another missing. Ukraine claimed to have shot it down, at a range of 308 km, using an S-200 missile, according to an interview with Lt. Gen. Kyrylo Budanov, head of the HUR. Russian authorities claimed the aircraft crashed due to a technical malfunction. Russian media reported that Russell Bentley, an American citizen and a resident of Donetsk Oblast who fought for pro-Russian separatists during the Donbas War was killed in unspecified circumstances after going missing following a Ukrainian attack on 8 April. His wife claimed that he had been abducted by Russian soldiers. Russian media outlets claimed that Izvestia war correspondent Semyon Eremin was killed by a Ukrainian drone strike after visiting a Russian unit in Zaporizhzhia Oblast.
The short length of pompilidotoxins implies that the crucial amino acid for receptor binding would be easier to detect in studies based on pompilidotoxins. Additionally, the binding of the α-scorpion or sea anemone toxin to the sodium receptor also includes a complex system of forming three to four additional disulfide bonds. Pompilidotoxins cannot form such bonds. Pompilidotoxins thus provide a special advantage to research, classify, and characterise different isoforms of sodium channels due to their concise and simple structure. They have already been used for neuronal research into the action mechanisms of sodium channels, and the characterisation of receptor functions. Knowing more about the working of sodium channels could greatly contribute to healthcare as sodium channel alterations are associated with a large range of neurological disorders. Persistent sodium currents are especially participating in some variants of epilepsy and MS. Moreover, β-PMTX itself has been associated with being an epilepsy-inducing agent due to its drastic working in increasing neuronal excitability and has been recognized as being especially important for providing insights into the role of sodium currents in epileptogenesis. Thus, even though pompilidotoxins are not used as drugs and therefore have no efficacious nor adverse effects, they are medically valuable as a research model to indirectly improve patient well-being.
Sources: en.wikipedia.org
2 FeCl3 + 2 H2O + SO2 → 2 FeCl2 + H2SO4 + 2 HCl 2 CuCl2 + 2 H2O + SO2 → 2 CuCl + H2SO4 + 2 HCl Two less well-known laboratory methods of producing sulfuric acid, albeit in dilute form and requiring some extra effort in purification, rely on electrolysis. A solution of copper(II) sulfate can be electrolyzed with a copper cathode and platinum/graphite anode to give spongy copper at cathode and oxygen gas at the anode. The solution of dilute sulfuric acid indicates completion of the reaction when it turns from blue to clear (production of hydrogen at cathode is another sign):
Another class of phytohormones is the jasmonates, first isolated from the oil of Jasminum grandiflorum which regulates wound responses in plants by unblocking the expression of genes required in the systemic acquired resistance response to pathogen attack. In addition to being the primary energy source for plants, light functions as a signalling device, providing information to the plant, such as how much sunlight the plant receives each day. This can result in adaptive changes in a process known as photomorphogenesis. Phytochromes are the photoreceptors in a plant that are sensitive to light.
Interest in, and demand for, embalming grew steadily in the 19th century largely for sentimental reasons. People sometimes wished to be buried at far-off locations, which became possible with the advent of the railways, and mourners wanted the chance to pay their last respects beside the displayed body. Other motives behind embalming were prevention of disease and the wish to prepare funerals and burials, which were becoming more elaborate, without undue haste. After Lord Nelson was killed in the Battle of Trafalgar, his body was preserved in brandy and spirits of wine mixed with camphor and myrrh for over two months. At the time of his state funeral in 1805, his body was found to still be in excellent condition and completely plastic.
=== BP Deepwater Horizon Research === In 2015 Cave won second place in the Intel International Science and Engineering Fair in the Earth & Environmental Sciences Category with her research on the BP Oil Spill impact. As a result, NASA and MIT Lincoln Laboratory renamed minor planet "2000 GD136" after her. She began her research at the University of New Orleans at 15, funded by GOMRI (Gulf of Mexico Research Initiative). The research, titled "A Method for Identifying the Photoproducts, Mechanisms, and Toxicity of Petroleum from the Deepwater Horizon by High-Performance Liquid Chromatography and DNPHi Derivatization," provided a method for the U.S. Environmental Protection Agency to identify nanotoxins that form in seawater after oil spills. Cave's method later became a spinoff project in Ecology and Evolutionary Biology conducted at Tulane University in 2016. During this time, Cave traveled with her lab to Gamboa, Panama to conduct research with the Smithsonian Tropical Research Institute.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.